01
Cash & equivalents increased 161.7%
Cash & equivalents changed +161.7% from the comparable as-filed period.
$35.5M→$92.8MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTLexeo Therapeutics, Inc.'s latest supported as-filed period reports revenue of $654,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +161.7% from the comparable as-filed period.
Net income changed +0.9% from the comparable as-filed period.
Operating income changed +8.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
LXEO · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0002083206-26-000007SEC ↗4Aug 19, 2026Period Aug 18, 20260001995218-26-000015SEC ↗4Aug 19, 2026Period Aug 18, 20260002024096-26-000013SEC ↗10-QAug 12, 2026Period Jun 30, 20260001193125-26-345724SEC ↗8-KAug 12, 2026Period Aug 12, 20260001193125-26-345722SEC ↗4Jul 1, 2026Period Jun 29, 20260002083206-26-000005SEC ↗4Jul 1, 2026Period Jun 29, 20260002024096-26-000011SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 18, 2026Filed Aug 19, 2026 | Tamayo Louis EdwardChief Financial Officer | Open Market SaleDirect | 4,117 | $5 | $20,203 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +29.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Stock-based compensation changed +85.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0002109299-26-000007